Conclusions
The present phase II trial demonstrated the feasibility of STAR in AF elderly patients, reporting also promising data in terms of safety, outcomes, and quality of life. This new non-invasive and outpatient therapeutic approach can represent a valid alternative for a rapidly growing category of patients.Close collaboration between radiation oncologists, cardiac electrophysiologists, and medical physics is paramount for this technique, to minimize patient risk and achieve highest levels of ablation accuracy. Further data are needed to confirm our results and to assess possible long- term side effects.